Eligibility of sacubitril–valsartan in a real-world heart failure population: a community-based single-centre study

ESC Heart Failure

Volumn 5, Issue 2, 2018, Pages 337-343

  Norberg, Helena ^a   Bergdahl, Ellinor ^a   Lindmark, Krister ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Eligibility; Heart failure; HFrEF; PARADIGM HF; Real world population; Sacubitril Valsartan

Indexed keywords

AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; SACUBITRIL PLUS VALSARTAN; TETRAZOLE DERIVATIVE;

AGED; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; FEMALE; FOLLOW UP; HEALTH SURVEY; HEART FAILURE; HEART RATE; HEART STROKE VOLUME; HUMAN; MALE; MIDDLE AGED; MORBIDITY; MULTICENTER STUDY; ORGANIZATION AND MANAGEMENT; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; RETROSPECTIVE STUDY; SURVIVAL RATE; SWEDEN; TREATMENT OUTCOME; TRENDS;

AGED; AMINOBUTYRATES; ANGIOTENSIN RECEPTOR ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELIGIBILITY DETERMINATION; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HEART RATE; HUMANS; MALE; MIDDLE AGED; MORBIDITY; POPULATION SURVEILLANCE; RETROSPECTIVE STUDIES; STROKE VOLUME; SURVIVAL RATE; SWEDEN; TETRAZOLES; TREATMENT OUTCOME;

EID: 85049843839     PISSN: None     EISSN: 20555822     Source Type: Journal    
DOI: 10.1002/ehf2.12251     Document Type: Article

References (28)

1. Zarrinkoub R, Wettermark B, Wandell P, Mejhert M, Szulkin R, Ljunggren G, Kahan T. The epidemiology of heart failure, based on data for 2.1 million inhabitants in Sweden. Eur J Heart Fail 2013; 15: 995–1002
2. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129–2200
3. SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302
4. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772–776
5. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S, Poole-Wilson PA. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009; 374: 1840–1848
6. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106: 2194–2199
7. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9–13
8. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709–717
9. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11–21
10. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, Investigators P-H, Committees. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993–1004
11. Yandrapalli S, Aronow WS, Mondal P, Chabbott DR. Limitations of sacubitril/valsartan in the management of heart failure. Am J Ther 2017; 24: e234–e239
12. Vaduganathan M, Desai AS. Angiotensin–neprilysin inhibition as a paradigm for all? Curr Cardiol Rep 2016; 18: 115
13. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz M, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, Investigators P-HC. Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail 2014; 16: 817–825
14. Maggioni AP, Orso F, Calabria S, Rossi E, Cinconze E, Baldasseroni S, Martini N. The real-world evidence of heart failure: findings from 41 413 patients of the ARNO database. Eur J Heart Fail 2016; 18: 402–410
15. Masoudi FA, Havranek EP, Wolfe P, Gross CP, Rathore SS, Steiner JF, Ordin DL, Krumholz HM. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. Am Heart J 2003; 146: 250–257
16. Hernandez AF, Mi X, Hammill BG, Hammill SC, Heidenreich PA, Masoudi FA, Qualls LG, Peterson ED, Fonarow GC, Curtis LH. Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction. JAMA 2012; 308: 2097–2107
17. Kennedy-Martin T, Curtis S, Faries D, Robinson S, Johnston J. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials 2015; 16: 495
18. Lazzarini V, Mentz RJ, Fiuzat M, Metra M, O'Connor CM. Heart failure in elderly patients: distinctive features and unresolved issues. Eur J Heart Fail 2013; 15: 717–723
19. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau J, Shi VC, Solomon SD, Swedberg K, Zile MR, Committees P-H, Investigators. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 2013; 15: 1062–1073
20. Pellicori P, Urbinati A, Shah P, MacNamara A, Kazmi S, Dierckx R, Zhang J, Cleland JGF, Clark AL. What proportion of patients with chronic heart failure are eligible for sacubitril–valsartan? Eur J Heart Fail 2017; 19: 768–778
21. Thorvaldsen T, Benson L, Dahlstrom U, Edner M, Lund LH. Use of evidence-based therapy and survival in heart failure in Sweden 2003–2012. Eur J Heart Fail 2016; 18: 503–511
22. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. The Lancet 2010; 376: 875–885
23. McMurray JJ, Krum H, Abraham WT, Dickstein K, Kober LV, Desai AS, Solomon SD, Greenlaw N, Ali MA, Chiang Y, Shao Q, Tarnesby G, Massie BM. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. N Engl J Med 2016; 374: 1521–1532
24. Cherubini A, Oristrell J, Pla X, Ruggiero C, Ferretti R, Diestre G, Clarfield AM, Crome P, Hertogh C, Lesauskaite V, Prada GI, Szczerbinska K, Topinkova E, Sinclair-Cohen J, Edbrooke D, Mills GH. The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch Intern Med 2011; 171: 550–556
25. Konrat C, Boutron I, Trinquart L, Auleley GR, Ricordeau P, Ravaud P. Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs. PloS one 2012; 7: e33559
26. Jhund PS, Fu M, Bayram E, Chen CH, Negrusz-Kawecka M, Rosenthal A, Desai AS, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, McMurray JJ, Packer M. Efficacy and safety of LCZ696 (sacubitril–valsartan) according to age: insights from PARADIGM-HF. Eur Heart J 2015; 36: 2576–2584
27. Forman DE, Ahmed A, Fleg JL. Heart failure in very old adults. Curr Heart Fail Rep 2013; 10: 387–400
28. Perez AL, Kittipibul V, Tang WHW, Starling RC. Patients not meeting PARADIGM-HF enrollment criteria are eligible for sacubitril/valsartan on the basis of FDA approval: the need to close the gap. J Am Coll Cardiol HF 2017; 5: 460–463